- English
- 简体中文
- Español
- Português
- русский
- Français
- 日本語
- Deutsch
- tiếng Việt
- Italiano
- Nederlands
- ภาษาไทย
- Polski
- 한국어
- Svenska
- magyar
- Malay
- বাংলা ভাষার
- Dansk
- Suomi
- हिन्दी
- Pilipino
- Türkçe
- Gaeilge
- العربية
- Indonesia
- Norsk
- تمل
- český
- ελληνικά
- український
- Javanese
- فارسی
- தமிழ்
- తెలుగు
- नेपाली
- Burmese
- български
- ລາວ
- Latine
- Қазақша
- Euskal
- Azərbaycan
- Slovenský jazyk
- Македонски
- Lietuvos
- Eesti Keel
- Română
- Slovenski
- मराठी
- Srpski језик
Sinae APIs Categoria Factory
Active Pharmaceutical Ingredientia
| Progestogen et Estrogen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Progesterone | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pregnenolone | In domo |
Kosher | 145-13-1 |
| Medroxyprogesterone Acetate | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetate | CP/EP/USP | DMF in processususus | 595-33-5 |
| Mifepristone | CP/IP | DMF/GMP | 84371-65-3 |
| Cyproterone Acetate | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| Levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Norethisterone |
CP/EP/USP/JP |
DMF in processususus |
68-22-4 |
| Norethisterone Acetate |
EP/USP |
DMF in processususus |
51-98-9 |
| Norethisterone Enanthate |
In domo |
Sub R&D |
3836-23-5 |
| Drospirenone | EP/USP | DMF | 67392-87-4 |
| Gestodene | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | Sub R&D | 50-27- 1 |
| Ethinyl Estradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerate | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol Cypionatus |
USP | DMF in processususus |
313-06-4 |
| Promestriene |
In domo |
Sub R&D |
39219-28-8 |
| Tibolone | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | Sub R&D | 129453-61-8 |
| Exemestane | CP/EP/USP | Sub R&D | 107868-30-4 |
| Androgen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Finasteride | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasteride | EP/USP | CEP/FDA | 164656-23-9 |
| Abiraterone Acetate | CP/USP | DMF/GMP/WC | 154229-18-2 |
| Darolutamide |
In domo |
Sub R&D |
1297538-32-9 |
| Testosterone | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosterone Undecanoate | CP | DMF/WC | 5949-44-0 |
| Testosterone Cypionate | USP | DMF | 58-20-8 |
| Testosterone Enanthate |
USP/JP | Sub R&D |
315-37-7 |
| Testosterone Propionate |
CP/EP/USP/JP |
Sub R&D |
57-85-2 |
| DHEA | FP/In domo | DMF/WC/Kosher | 53-43-0 |
| Clascoterone | In domo | DMF in processususus | 19608-29-8 |
| Cortical Hormone | |||
| Product Name | Specification | Probatus | CAS Non. |
| Budesonide | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonide | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenone | EP | CEP in processuu | 107724-20-9 |
| Methylprednisolone | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Methylprednisolone Hemisuccinate | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Fluticasone Propionate | CP/EP/USP | DMF | 80474- 14-2 |
| Fluticasone Furoate | CP/EP | DMF in processususus | 397864-44-7 |
| Mometasone Furoate |
CP/EP/USP |
DMF in processususus |
Anhydrous (83919-23-7) Monohydratorum (141646-00-6) |
| Deflazacort |
In domo |
Sub R&D |
14484-47-0 |
| alii | |||
| Product Name | Specification | Probatus | CAS Non. |
| Oxcarbazepine | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslicarbazepine Acetate | CP/USP | DMF | 236395- 14-5 |
| Ganciclovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciclovir Hydrochloride | USP/EP | CEP in processu | 175865-59-5 |
| Oseltamivir Phosphate | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | In domo | Sub R&D | 1985606-14-1 |
| Revefenacin | In domo | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
In domo |
Sub R&D |
1190389-15-1 |
| Escitalopram Oxalate | CP/EP/USP | DMF in processusus | 219861-08-2 |
| Citalopram Hydrobromide |
CP/EP/USP |
DMF in processususus |
59729-32-7 |
| Cariprazine hydrochloride | In domo | DMF | 1083076-69-0 |
| Lasmiditan Succinate | In domo | DMF | 439239-92-6 |
| Iuliconazole | In domo | DMF | 187164-19-8 |
| Nintedanib Esylate |
In domo |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | In domo | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | Sub R&D | 171596-29-5 |
| Relugolix | In domo | DMF in processusus | 737789-87-6 |
| Ruxolitinib phosphate |
In domo |
DMF in processususus |
1092939-17-7 |
| Abemaciclib |
In domo |
Sub R&D |
1231929-97-7 |
| Phloroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-Trimethoxybenzene |
CP/In-domus |
GMP |
621-23-8 |
| Acidum Ursodeoxycholic | EP/USP/JP | Sub R&D | 128-13-2 |
| Tauroursodeoxycholic Acid |
In domo |
Sub R&D |
14605-22-2 |
| Cura |
CP/EP/USP/JP |
Sub R&D |
57-88-5 |
| Omega-3-Acid Ethyl Ethers 90 |
EP/USP |
DMF in processususus |
-- |
| Medium-Chain Triglycerides |
CP/USP/EP |
DMF |
-- |
| Benzalkonium Chloride |
USP/EP/JP |
CEP in processuu |
8001-54-5 |
| Oleum olivae (For Iniectio) |
CP/USP/EP/JP |
DMF in processususus |
8001-25-0 |
| Ovum phospholipids (nam Iniectio) |
CP/USP/EP |
DMF |
93685-90-6 |
| PORTIO |
In domo |
DMF in processususus |
203787-91-1 |
- View as
Lasmiditan Succinate
Lasmiditan Succinatus habet specificationem In-domus. DMF probatus.
CAS:439239-92-6
Lege plusMitte Inquisitionem
Cariprazinum hydrochloridum
Cariprazinum hydrochloridum in specificatione-domum habet. DMF probatus.
CAS: 1083076-69-0
Lege plusMitte Inquisitionem
Mirabegron
Mirabegron habet specificationem in domo. DMF probatus est.,.
CAS:223673-61-8
Lege plusMitte Inquisitionem
Luliconazole
Luliconzole habet in-Domus specificationem: DMF probatus.
CAS: 187164-19-8
Lege plusMitte Inquisitionem
Humanwell Pharmaceuticus unus ex maximis API fabricandis in Sinis. Cum plusquam XX annos experientiae, APIs, intermediis et formulis elaboramus, fabricamus et mercaturas steroidales. Forum nostrum toto orbe terrarum operit, praesentias validas habemus in America Septentrionali, Europa, America Meridionali et Africa, cum fructibus plus quam 150 terris venditis.
